Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Jan 7;2(1):5-9.
doi: 10.1159/000323472.

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C

Miho Soma  1 , Akira Hirata, Takamitsu Takahashi, Satoshi Okinami
Affiliations
Case Reports

Relapse of Vogt-Koyanagi-Harada Disease during Interferon-α and Ribavirin Therapy in a Case of Chronic Viral Hepatitis C

Miho Soma et al. Case Rep Ophthalmol. .

Abstract

A 60-year-old woman, who had been diagnosed with and treated for Vogt-Koyanagi-Harada (VKH) disease 17 years before, was receiving pegylated interferon-? and ribavirin therapy for chronic hepatitis C virus. Three weeks after the start of therapy, she complained of visual blurring, eye pain, and an increased hearing loss. Based on a slit lamp and fundus examination, she was diagnosed with a relapse of VKH disease. After discontinuation of the pegylated interferon-α and ribavirin therapy and administration of corticosteroid therapy, her visual acuity returned to 1.0 in both eyes without ocular inflammation, and remained stable thereafter. When interferon therapy is administered to hepatitis C virus patients, those who also have a history of VKH disease must be closely monitored for ophthalmologic complications.

Keywords: Chronic hepatitis C virus; Interferon-α; Vogt-Koyanagi-Harada disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Fluorescein angiographic features of the patient at the initial onset of VKH disease in April 1991. Fluorescein angiography shows multiple locations of pinpoint subretinal leakage and serous retinal detachment. a Right eye. b Left eye.
Fig. 2
Fig. 2
Fundus photographs of the patient at the second onset of VKH disease in June 2008 after the start of PEG-IFN and ribavirin therapy. Both eyes show a sunset appearance with serous detachment (a, b). Fluorescein angiography shows multiple locations of pinpoint subretinal leakage corresponding to serous retinal detachment (c, d). a, c Right eye. b, d Left eye.
See this image and copyright information in PMC

References

    1. Okada AA, Keino H, Fukai T, Sakai J, Usui M, Mizuguchi J. Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm. 1998;6:215–226. - PubMed
    1. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Huong du LT, Lemaitre C, Fradeau C, LeHoang P, Piette JC. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–339. - PMC - PubMed
    1. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother. 1999;53:242–254. - PubMed
    1. Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006;7:451–456. - PubMed
    1. Kasahara A, Hiraide A, Tomita N, Iwahashi H, Imagawa A, Ohguro N, Yamamoto S, Mita E, Hayashi N. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol. 2004;39:1106–1109. - PubMed

Publication types